NCT06485947View on ClinicalTrials.gov

Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

July 1, 2030

Study Completion Date

December 1, 2031

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

Dinutuximab beta

Combination of immunotherapy with standard chemotherapy

DRUG

chemotherapy treatment called GPOH

chemotherapy treatment called GPOH

DRUG

chemotherapy treatment called rapid COJEC

chemotherapy treatment called rapid COJEC

Trial Locations (1)

3584 CS

RECRUITING

Princess Maxima center for pediatric oncology, Utrecht

Sponsors

Collaborators (1)

EUSA Pharma, Inc.
All Listed Sponsors
collaborator

EUSA Pharma, Inc.

INDUSTRY

lead

Princess Maxima Center for Pediatric Oncology

OTHER

NCT06485947 - Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma | Biotech Hunter | Biotech Hunter